Derma Sciences (DSCI) Prelim. Q4, FY15 Sale Miss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Derma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial Guidance
January 7, 2016 7:30 AM ESTReduces non-R&D operating expenses by approximately $10.0 million through workforce reductions, expense cuts and cost-savings initiatives Expects 13% AWC growth in 2016 and positive cash flow for the second half of the year
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, provides preliminary net sales for the year ended December 31, 2015, announces various actions to reduce operating expenses and introduces financial guidance for the year ending December 31, 2016.
For the year ended December 31, 2015:
... More